Astragalin is a flavonoid compound found in various plants, including Polygonum aviculare, Kaempferia galanga, and Astragalus membranaceus. Recent preclinical research has explored its potential in managing psoriasis, primarily due to its anti-inflammatory and antioxidant properties. Several in vitro and animal studies have demonstrated that astragalin can inhibit the production of pro-inflammatory cytokines such as TNF-α, IL-17, and IL-23, which are key mediators in the pathogenesis of psoriasis. For example, a 2021 study by Liu et al. in a mouse model of imiquimod-induced psoriasis-like dermatitis found that topical administration of astragalin significantly reduced epidermal thickness and inflammatory infiltration, likely through suppression of the NF-κB and STAT3 signaling pathways.

Despite these promising findings, there is currently a lack of published clinical trials evaluating astragalin's efficacy and safety in humans with psoriasis. Therefore, while the evidence base is growing at the preclinical level, it is not yet strong enough to recommend astragalin as a validated treatment for psoriasis in clinical practice. No traditional or historical use specifically ties astragalin to psoriasis in ethnomedicine. Thus, the current support for its use in psoriasis is primarily scientific, with evidence strength rated at 2 out of 5, reflecting promising preclinical results but insufficient clinical validation.